We serve Chemical Name:3,6-dichloroquinolin-8-amine CAS:158117-56-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,6-dichloroquinolin-8-amine
CAS.NO:158117-56-7
Synonyms:3,6-Dichloro-8-quinolinamine;3,6-Dichloro-8-quinolinylamine;8-amino-3,6-dichloroquinoline
Molecular Formula:C9H6Cl2N2
Molecular Weight:213.06300
HS Code:2933499090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.91000
Exact Mass:211.99100
LogP:3.70500
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3,6-Dichloro-8-quinolinamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,8-amino-3,6-dichloroquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,6-Dichloro-8-quinolinamine Use and application,8-amino-3,6-dichloroquinoline technical grade,usp/ep/jp grade.
Related News: Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. 2,7-Dimethoxy-3,6-bis(methylthio)-naphthalene manufacturers For its part, the FDA’s representative at the meeting, Doran Fink, M.D., said the drug regulator is “working as rapidly as possible to conduct a thorough and comprehensive” review of all the COVID-19 vaccines that have applied for full approval. Pfizer and Moderna recently submitted their applications for a full nod. Henicosanyl palmitate suppliers With its offering of API development, GMP manufacturing, solid state chemistry and analytical expertise, Onyx continues to experience strong growth driven by demand from biotech and pharmaceutical companies for its integrated CMC capabilities. Methyl 4-amino-2-bromobenzoate vendor & factory “Partnering with a CDMO that has the skills and capabilities to execute a successful tech transfer is critical, as this complex, multi-step process helps lay the foundation for the new drug’s journey through to commercialization. ,For its part, the FDA’s representative at the meeting, Doran Fink, M.D., said the drug regulator is “working as rapidly as possible to conduct a thorough and comprehensive” review of all the COVID-19 vaccines that have applied for full approval. Pfizer and Moderna recently submitted their applications for a full nod.
